NACTN study gains momentum

Posted by Reeve Staff in Daily Dose on September 09, 2016 # Research

The Christopher & Dana Reeve Foundation's North American Clinical Trials Network (NACTN), with funding from the Department of Defense (DOD), is partnering with AOSpine North America in RISCIS (Riluzole in Spinal Cord Injury Study). The Phase II/III clinical trial is a multi-center, randomized, placebo-controlled double-blinded study that will enroll 351 patients with acute cervical spinal cord injuries. The DOD funding also enables NACTN sites to conduct a RISCIS sub-study, the pharmacology of riluzole, to determine optimal dosage of the drug.

Learn more by visiting our Research page.

The National Paralysis Resource Center website is supported by the Administration for Community Living (ACL), U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $8,700,000 with 100 percent funding by ACL/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by ACL/HHS, or the U.S. Government.